Back to Search
Start Over
Merck and Bayer's Investigational Drug Vericiguat Meets Primary Endpoint in Phase 3 Study of Patients with Worsening Chronic Heart Failure
- Source :
- Cardiovascular Week. December 2, 2019, 89
- Publication Year :
- 2019
-
Abstract
- 2019 DEC 2 (NewsRx) -- By a News Reporter-Staff News Editor at Cardiovascular Week -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that the [...]
Details
- Language :
- English
- ISSN :
- 15436853
- Database :
- Gale General OneFile
- Journal :
- Cardiovascular Week
- Publication Type :
- News
- Accession number :
- edsgcl.607173092